HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.

Abstract
Dupilumab inhibits T-helper 2 (Th2)-driven inflammation cascade by blocking interleukin-4 (IL-4) and IL-13 signaling, which has been recognized to play a crucial role in the pathogenesis of atopic dermatitis (AD) and shown encouraging efficacy on moderate to severe AD.1 We report an interesting Chinese AD case, which developed into pustular psoriasis after treatment with dupilumab.
AuthorsXinrui Jia, Chanchan Li, Jianbo Wu, Qin Liu
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 21 Issue 3 Pg. 311-312 (Mar 01 2022) ISSN: 1545-9616 [Print] United States
PMID35254760 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • dupilumab
Topics
  • Antibodies, Monoclonal, Humanized (adverse effects)
  • Dermatitis, Atopic (diagnosis, drug therapy, pathology)
  • Eczema
  • Humans
  • Psoriasis (diagnosis, drug therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: